Antitope and Eden Biodesign Enter Into a Research Agreement
Published: Feb 06, 2013
Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope commented, "We are very pleased to work with Eden Biodesign and assist in the development of their antibody therapeutics. The partnership combines Antitope's core technologies in the generation of high-yielding manufacturing cell lines for the production of therapeutic antibodies with Eden Biodesign’s extensive experience in biopharmaceutical discovery, process development and GMP manufacturing."
Dr Crawford Brown, Chief Executive Officer of Eden Biodesign, Ltd., a member of the Watson Group, added: “After a careful and diligent search for a partner capable of both meeting our exacting quality standards and delivering highly productive and compliant cGMP production cell lines, we are very happy to be working with Antitope on this important project.”
Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in the generation of humanised antibodies devoid of T cell epitopes. Antitope's proprietary Composite CHO™ and cell line development technologies result in the generation of high yielding manufacturing cell lines suitable for transfer to CMOs and GMP manufacturing. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
For more information, please visit www.antitope.co.uk or contact:
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190